Drugs / ANB-004
ANB-004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05747261 | Feb 2023 → Sep 2025 overdue | spinal muscular atrophy | Biocad | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANB-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05747261 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated viral vector carrying the SMN gene” NCT05747261 ↗ |
| Route | Intravenous | “each of whom will receive a pre-specified cohort dose of ANB-004 as a single intravenous infusion.” NCT05747261 ↗ |
| Target | SMN | “Adeno-associated viral vector carrying the SMN gene” NCT05747261 ↗ |